NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SRPT

Sarepta Therapeutics Inc

Apr 17 • 04:00PM ET

53.79

Dollar change -0.15
Percentage change -0.28	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: VTI IJH VB VXF VBK XBI MDY IJK IBB IWP

Scroll to Statements

Index	-	P/E	22.57	EPS (ttm)	2.38	Insider Own	6.07%	Shs Outstand	96.90M	Perf Week	6.92%
Market Cap	5.22B	Forward P/E	4.22	EPS next Y	12.75	Insider Trans	-0.25%	Shs Float	91.14M	Perf Month	-32.74%
Income	235.24M	PEG	0.24	EPS next Q	-3.14	Inst Own	91.93%	Short Float	6.69%	Perf Quarter	-54.05%
Sales	1.90B	P/S	2.74	EPS this Y	72.80%	Inst Trans	3.25%	Short Ratio	3.30	Perf Half Y	-56.53%
Book/sh	15.77	P/B	3.41	EPS next Y	238.29%	ROA	6.51%	Short Interest	6.10M	Perf Year	-54.14%
Cash/sh	13.96	P/C	3.85	EPS next 5Y	92.98%	ROE	19.71%	52W Range	48.01 - 173.25	Perf YTD	-55.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	8.23%	52W High	-68.95%	Beta	0.89
Dividend TTM	-	Quick Ratio	3.18	Sales past 5Y	38.19%	Gross Margin	81.24%	52W Low	12.04%	ATR (14)	4.56
Dividend Ex-Date	-	Current Ratio	4.20	EPS Y/Y TTM	140.26%	Oper. Margin	11.47%	RSI (14)	31.45	Volatility	5.01% 6.95%
Employees	1372	Debt/Eq	0.88	Sales Y/Y TTM	52.97%	Profit Margin	12.37%	Recom	1.40	Target Price	156.87
Option/Short	Yes / Yes	LT Debt/Eq	0.87	EPS Q/Q	272.83%	Payout	0.00%	Rel Volume	1.03	Prev Close	53.94
Sales Surprise	4.91%	EPS Surprise	-20.32%	Sales Q/Q	65.94%	Earnings	Feb 26 AMC	Avg Volume	1.85M	Price	53.79
SMA20	-11.52%	SMA50	-37.31%	SMA200	-54.34%	Trades		Volume	1,912,205	Change	-0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-11-25	Initiated	Wells Fargo	Overweight	$115
Apr-02-25	Upgrade	H.C. Wainwright	Sell → Neutral	$75
Mar-31-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$161 → $87
Feb-11-25	Initiated	Deutsche Bank	Hold	$136
Nov-27-24	Reiterated	Needham	Buy	$205 → $202
Nov-25-24	Initiated	H.C. Wainwright	Sell	$80
Nov-07-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$152 → $167
Oct-21-24	Initiated	Jefferies	Buy	$165
Oct-10-24	Resumed	Raymond James	Outperform	$150
Jul-29-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$182
Jun-26-24	Downgrade	Citigroup	Buy → Neutral	$172 → $176
May-31-24	Initiated	Piper Sandler	Overweight	$157
May-28-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$157 → $142
May-14-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jan-31-24	Initiated	BMO Capital Markets	Outperform	$170
Dec-13-23	Resumed	Citigroup	Buy	$113
Dec-12-23	Initiated	Deutsche Bank	Buy	$109
Nov-21-23	Initiated	Wedbush	Outperform	$224
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$166 → $40

Show Previous Ratings

Apr-16-25 07:32AM	SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies (Zacks)
Apr-15-25 08:30AM	Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs (Business Wire)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -9.60%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks) +12.88%
04:50PM	Loading…
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -5.92%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
05:14AM	3 Reasons to Avoid SRPT and 1 Stock to Buy Instead (StockStory)
Apr-07-25 08:09AM	4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street (Motley Fool)
07:21AM	Sarepta and Roche aim to resume paused Elevidys trials following patient death (Clinical Trials Arena)
Apr-04-25 10:38AM	Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death (Investopedia) -7.13%
09:25AM	Sarepta price target lowered to $183 from $202 at Needham (TipRanks)
08:44AM	Sarepta Therapeutics Provides Update on ELEVIDYS (Business Wire)
07:29AM	SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy (Zacks)
Apr-03-25 04:27PM	Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy (Investor's Business Daily) -6.18%
03:37PM	Loading…
03:37PM	BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (Seeking Alpha)
03:23PM	Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death (Benzinga)
08:58AM	Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death (Investor's Business Daily)
07:19AM	Roche halts testing of Sarepta Duchenne gene therapy in Europe (BioPharma Dive)
Apr-01-25 12:40PM	Sarepta price target lowered to $179 from $210 at BofA (TipRanks)
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
12:15PM	3 Market Predictions For April (Seeking Alpha)
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
Mar-31-25 05:54PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.36%
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
01:29PM	Why Sarepta Therapeutics (SRPT) Stock Is Nosediving (StockStory)
11:05AM	Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street (The Wall Street Journal)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
09:31AM	Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out (The Wall Street Journal)
04:17PM	Loading…
Mar-29-25 04:17PM	Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-28-25 11:30AM	Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? (Zacks)
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha)
10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-23-25 09:30AM	Is This Stock a Buy After a Massive 20% Drop in 1 Day? (Motley Fool)
07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 04:46AM	The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics (Zacks)
Mar-20-25 01:55PM	Sarepta: Should Investors Run For The Exit? (SeekingAlpha) -8.15%
12:45PM	Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More (Zacks)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
01:58AM	Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength? (Zacks)
Mar-19-25 09:02PM	Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday? (InsiderMonkey) +8.74%
01:38PM	SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion (Zacks)
09:28AM	Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? (Insider Monkey)
08:57AM	Company News for Mar 19, 2025 (Zacks)
Mar-18-25 04:01PM	Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened. (Investor's Business Daily) -27.44%
11:55AM	Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today (StockStory)
10:42AM	Patient dies following muscular dystrophy gene therapy, Sarepta reports (Associated Press Finance)
10:29AM	Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies (Investopedia)
10:21AM	Gene-Therapy Maker Sarepta Tanks After Patient Death (The Wall Street Journal)
10:21AM	Gene Therapy Maker Tanks After Patient Death (The Wall Street Journal)
10:17AM	Patient Dies After Receiving Sareptas Gene Therapy (Barrons.com)
10:08AM	Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies (Investor's Business Daily)
09:29AM	Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges (Benzinga)
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-28-25 10:20AM	Sarepta price target lowered to $210 from $217 at BofA (TipRanks)
09:00AM	Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program (Business Wire)
Feb-27-25 08:50AM	Q4 2024 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:19AM	Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-26-25 11:00PM	Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript (Motley Fool)
05:25PM	Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates (Zacks)
04:36PM	Sarepta Therapeuticss (NASDAQ:SRPT) Q4: Beats On Revenue (StockStory)
04:23PM	Sarepta Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments (Business Wire)
09:55AM	Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Feb-25-25 12:29PM	Sarepta Therapeutics, Inc. (SRPT): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
08:03AM	Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-20-25 02:12PM	Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now? (Insider Monkey)
Feb-17-25 09:35AM	Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround (Zacks)
Feb-14-25 08:30AM	Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility (Business Wire)
Feb-12-25 08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results (Business Wire)
Feb-11-25 10:10AM	Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-10-25 08:30AM	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (Business Wire)
Feb-09-25 09:10AM	2 Growth Stocks to Buy Hand Over Fist in February (Motley Fool)
Feb-08-25 09:18AM	Why Sarepta Therapeutics, Inc. (SRPT) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Jan-31-25 08:36AM	Jim Cramer Says I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science (Insider Monkey)
Jan-30-25 10:35AM	Sarepta could be down on patient death in FDA database, says RBC Capital (TipRanks)
Jan-28-25 05:28AM	Roche reports positive topline outcomes from DMD treatment trial (Clinical Trials Arena)
Jan-27-25 01:00AM	Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS (Business Wire)
Jan-20-25 07:52AM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
Jan-15-25 09:00PM	Lightning Round: Sell Viking Therapeutics, says Jim Cramer (CNBC TV)
Jan-13-25 12:25PM	Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue (Business Wire) -5.10%
Jan-07-25 11:19AM	Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference (PR Newswire)
Jan-06-25 08:30AM	Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 04:10PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-29-24 06:45AM	Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-23-24 10:04AM	Is Sarepta Therapeutics, Inc. (SRPT) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-19-24 11:25AM	Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial (Clinical Trials Arena)
Dec-18-24 08:30AM	Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 (Business Wire)
06:45AM	Tessera gets sickle cell funding; Corvus shares slide on eczema data (BioPharma Dive)
Dec-14-24 09:16PM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
Dec-13-24 09:55AM	Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High? (Zacks)
Dec-06-24 11:31AM	Why Is Sarepta Therapeutics (SRPT) Up 4.9% Since Last Earnings Report? (Zacks)
Nov-30-24 06:00AM	Arrowhead price target lowered to $24 from $27 at Bernstein (TipRanks)
Nov-29-24 04:10PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-28-24 08:15AM	Sarepta price target lowered to $202 from $205 at Needham (TipRanks)
Nov-27-24 09:55AM	Wall Street Analysts Think Sarepta Therapeutics (SRPT) Could Surge 42.11%: Read This Before Placing a Bet (Zacks) +5.70%
07:21AM	Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments (TipRanks)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nicaise Claude	Director	Mar 12 '25	Option Exercise	25.18	9,746	245,404	30,303	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Sale	99.64	2,491	248,203	27,812	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Proposed Sale	99.65	2,491	248,226		Mar 12 05:33 PM
Estepan Ian Michael	Chief Financial Officer	Jan 29 '25	Option Exercise	12.00	15,800	189,600	49,496	Jan 31 08:30 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Option Exercise	13.71	10,500	143,955	33,340	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Sale	124.84	10,500	1,310,820	22,840	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Proposed Sale	124.80	10,500	1,310,400		Dec 12 05:06 PM
Boor Kathryn Jean	Director	Dec 05 '24	Sale	125.55	1,636	205,400	5,880	Dec 06 08:00 PM
Boor Kathryn Jean	Director	Dec 05 '24	Proposed Sale	125.55	1,636	205,400		Dec 05 04:18 PM
Estepan Ian Michael	Chief Financial Officer	Aug 30 '24	Sale	137.36	5,985	822,100	33,946	Sep 03 08:00 PM
Estepan Ian Michael	Officer	Aug 30 '24	Proposed Sale	137.37	5,985	822,130		Aug 30 05:03 PM
Chambers Michael Andrew	Director	Aug 16 '24	Buy	133.80	37,038	4,955,728	284,034	Aug 20 08:00 AM
BEHRENS M KATHLEEN	Director	Jul 03 '24	Option Exercise	13.90	15,000	208,500	191,839	Jul 08 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Jun 25 '24	Option Exercise	62.77	23,500	1,475,095	56,086	Jun 25 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Jun 25 '24	Sale	161.61	38,957	6,296,029	17,129	Jun 25 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Jun 24 '24	Sale	163.08	7,859	1,281,621	21,261	Jun 25 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Jun 25 '24	Sale	163.23	3,898	636,271	17,363	Jun 25 08:00 PM
Murray Dallan	Chief Customer Officer	May 02 '24	Sale	140.00	3,635	508,900	18,125	May 06 08:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience